Arthritis Animation Rheumatology

Musculoskeletal Center Wins $2.2 Million For Drug Safety
The University of Alabama at Birmingham (UAB) Center for Education and Research on Therapeutics (CERTs) has won a $2.2 million federal grant to study the risks and benefits of a newer class of medicines called biologics. These are genetically engineered therapies that target the immune system of patients who have rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.

Grape Powder Alleviates Joint Inflammation - Constituents In Grapes Have Antihyperalgesic Effects In A Rat Model Of Joint Inflammation
Johns Hopkins Researchers at Neuroscience 2008 - Table grapes are high in flavonoids, which are thought to have strong antioxidant and anti-inflammatory properties. Now, researchers at the Johns Hopkins University School of Medicine have shown that powdered grapes appear to reduce pain and inflammation in a rat model of arthritis, where rats knees are inflamed using a chemical injection.

Rheumatoid Arthritis - Cimzia(R) Studies Show Significant Clinical Benefits For Mono- And Combination Therapy
UCB today announced the results of two phase III studies, published in the Annals of the Rheumatic Diseases Online, showing Cimzia® (certolizumab pegol), the only PEGylated anti-TNFalpha (Tumour Necrosis Factor alpha), provided significant clinical benefits as monotherapy, and in combination with methotrexate, in adults with active rheumatoid arthritis (RA).

FDA Clears The DPL (Deep Penetrating Light) Therapy System For Over-the-Counter - Home Use
LED Technologies, LLC announced today that the U.S. Food and Drug Administration (FDA) cleared their DPL™ Therapy System for the relaxation of muscles and relief of muscle spasms, temporary relief of minor muscle and joint aches, pains and stiffness; temporary relief of minor pain and stiffness associated with arthritis; and to temporarily increase local blood circulation.

New One-Stop Diabetic Rheumatology Clinic Is First In UK
Diabetes Mellitus is one of the most common chronic disorders in the population, affecting some 2 million people in the UK. Patients with diabetes (both Type 1 and 2) suffer an array of rheumatic complaints which are wide-ranging in nature and are often complex in management.

New Data Points To Long Lasting Beneficial Effects Of CEL-SCI's Rheumatoid Arthritis Vaccine
CEL-SCI Corporation (NYSE: CVM) announced the presentation of new rheumatoid arthritis data at the 6th annual GTCbio Vaccine Conference in Vienna, Va. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI, indicate that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000 prevents or retards the permanent tissue damage caused by rheumatoid arthritis.

Arthritis - MorphoSys Publishes Preclinical Data From MOR103 Program
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.

Actelion's First-in-class Selective S1P1 Receptor Agonist To Enter Phase II Clinical Development
Actelion Ltd (SWX: ATLN) announced that Actelion and Roche have jointly agreed that preclinical and clinical data support progressing Actelion's S1P1 receptor agonist into Phase II clinical development. An update will be presented at Actelion Day 2009, an event held at Actelion's headquarters in Allschwil on 19 February 2009. This event will be a combination of Actelion's annual Media and Analyst Conference and its Research and Development Day.

Staffordshire Arthritis Patients To Take Part In Major New Keele University Study
A team of researchers at Keele University in Staffordshire, UK, are hoping to improve the care and treatment of painful osteoarthritis offered by GPs in a major project involving almost 2,000 local patients. The study is being funded by a five-year grant of more than £788,000 from the Arthritis Research Campaign.

Rheumatoid Arthritis Breakthrough - Plos Biology
Rheumatoid arthritis is a painful, inflammatory type of arthritis that occurs when the body's immune system attacks itself. A new paper, published in this week's issue of PLoS Biology, reports a breakthrough in the understanding of how autoimmune responses can be controlled, offering a promising new strategy for therapy development for rheumatoid arthritis.

Physical Activity, Mobility And Health Across Lifespan Supported By CIHR Institute
We all know physical activity is good for you.

New Data Suggest Initial Use Of Abbott's HUMIRA® (adalimumab) May Help Prevent Further Joint Damage For Up To Five Years
New data show half of patients with moderate to severe early rheumatoid arthritis showed no progression of joint damage at five years. These results were seen in patients who initially received HUMIRA® (adalimumab) in combination with methotrexate (MTX) for two years and continued on HUMIRA for an additional three years in an open-label extension study. These results were presented this week at the American College of Rheumatology annual meeting in San Francisco.

Morria Biopharmaceuticals Plc Announces Positive Clinical Results For MRX-4 In Its Phase II Clinical Study In Allergic Rhinitis Patients
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season.

One In Ten Americans Suffers Arthritis Pain
Approximately 21 million Americans - 9.5 percent of adults 18 and older - either visited or called a doctor for a prescription to reduce arthritis pain in 2005, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The most common form of arthritis is osteoarthritis. It is usually associated with aging and most often causes pain and stiffness in the fingers, knees, and hips.

New Data Shows ACTEMRA Inhibits Progression Of Joint Destruction And Improves Physical Function Of Patients With Rheumatoid Arthritis
Roche announced that the innovative new therapy ACTEMRA (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA) this is a critical measure of effectiveness of an RA treatment. ACTEMRA was also found to improve the patients' physical function after one year of therapy and to significantly increase the disease remission rate.